palonosetron
Selected indexed studies
- Palonosetron. (Drugs, 2004) [PMID:15139789]
- Fosrolapitant/Palonosetron: First Approval. (Drugs, 2025) [PMID:40991189]
- Palonosetron (Helsinn). (Curr Opin Investig Drugs, 2002) [PMID:12431027]
_Worker-drafted node — pending editorial review._
Connections
palonosetron is a side effect of
Sources
- Palonosetron. (2004) pubmed
- Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. (2022) pubmed
- Fosrolapitant/Palonosetron: First Approval. (2025) pubmed
- Palonosetron (Helsinn). (2002) pubmed
- Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis. (2023) pubmed
- Palonosetron: in the prevention of nausea and vomiting. (2009) pubmed
- Effect of Palonosetron on Physical Symptoms of Surgical Patients: A Systematic Review and Meta-Analysis. (2022) pubmed
- Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. (2025) pubmed
- Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. (2006) pubmed
- Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. (2021) pubmed